Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Carenox, Maridolor, Merlodon, Oxycodon, Oxycontin, Oxynorm; Belgium: OxyContin, Oxynorm; Bulgaria: OxyContin; Czech Republic: Oxycodon, Oxycontin; Denmark: Oxycontin, Oxynorm; Estonia: Oxycontin; Finland: Oxanest, Oxycodone, Oxycontin, Oxynorm; France: Eubine, Oxycontin, Oxynorm, Oxynormoro; Germany: Kandocal, Oxyco, Oxycodolor, Oxycodon, Oxycontin, Oxygesic, Oxynorm; Greece: Oxycontin; Hungary: Oxycontin; Ireland: Dancex, Oxycontin, Oxydon, Oxynorm; Italy: Oxycontin; Netherlands: Oxycodon, Oxycontin; Oxynorm; Poland: Oxycontin; Portugal: Oxycontin, Oxynorm, Oxynormoro; Romania: Oxycontin; Slovakia: Oxycontin, Oxykodón, Oxykosan; Slovenia: Carexil, Oksikodon, Oxycontin; Spain: Oxycontin, Oxynorm; Sweden: Oxycodone, Oxycontin, Oxynorm; UK: Oxycontin, Oxynorm.

North America

Canada: Oxycodone, Oxycontin, Oxy.IR, Supeudol; USA: Oxycodone Hydrochloride, Oxycontin, Roxicodone.

Latin America

Argentina: Oxicalmans, Oxinovag, Oxycontin; Brazil: Oxycontin.


Japan: Oxycontin, Oxynorm, Roxicodone.

Drug combinations

Oxycodone and Acetaminophen

Oxycodone and Aspirin

Oxycodone and Ibuprofen

Oxycodone and Naloxone


Oxycodone: C~18~H~21~NO~4~. Mw: 315.36. (1) Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5α)-; (2) 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; (3)(-)-14-Hydroxydihydrocodeinone. CAS-76-42-6 (1963).

Oxycodone Hydrochloride: C~18~H~21~NO~4~ HCl. Mw: 351.82. Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride, (5α)-. CAS-124-90-3 (1966).

Pharmacologic Category

Analgesics and Antipyretics; Opiate Agonists. (ATC-Code: N02AA05).

Mechanism of action

Principal pharmacologic effects on CNS and intestines. Acts at several sites within CNS involving several systems of neurotransmitters to produce analgesia. Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering perception of and response to pain. Produces generalized CNS depression.

Therapeutic use

Moderate-to-severe pain, normally used in combination with nonopioid analgesics.

Pregnancy and lactiation implications

Should be used in pregnancy only if clearly needed. Use of narcotics during pregnancy may produce physical dependence in neonate. Respiratory depression may occur in newborn if narcotics used prior to delivery. Enters breast milk (use caution).

Unlabeled use


Hypersensitivity to oxycodone or any component of the formulation. Significant respiratory depression. Hypercarbia. Acute or severe bronchial asthma. Paralytic ileus. Pregnancy.

Warnings and precautions

May cause CNS depression (caution in CNS depression or coma). Effects may be potentiated when used with other sedative drugs or ethanol. Use with caution in history of seizure disorders. May cause hypotension (caution in hypovolemia, cardiovascular disease, or drugs which may exaggerate hypotensive effects). Use with caution in hypersensitivity reactions to other phenanthrene-derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxymorphone). May obscure diagnosis or clinical course of patients with acute abdominal conditions. Use with caution in adrenocortical insufficiency, including Addison’s disease, in biliary tract dysfunction (acute pancreatitis may cause constriction of sphincter of Oddi). Use with extreme caution in head injury, intracranial lesions, or elevated intracranial pressure (exaggerated elevation of intracranial pressure may occur). Use with caution in severe hepatic dysfunction, in morbidly obese patients, in prostatic hyperplasia and/or urinary stricture, in toxic psychosis, in severe renal dysfunction, and in pre-existing respiratory compromise (hypoxia and/or hypercapnia), chronic obstructive pulmonary disease or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages (use with caution in debilitated patients). Use with caution in thyroid dysfunction, and in the elderly (may be more sensitive to adverse effects). Use oral concentrate formulation with caution in latex sensitivity (dropper dispenser contains dry, natural rubber). Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with μ-opioid agonists. Use with caution in history of drug abuse or acute alcoholism (potential for drug dependency exists; tolerance, psychological and physical dependence may occur with prolonged use). Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms. Some quinolones may produce false-positive urine screening result for opiates using commercially-available immunoassay kits.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart